Teva launches Olanzapine and Fluoxetine Capsules for treatment of depression

Download PDF Copy

Jun 22 2012

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the launch of Olanzapine and Fluoxetine Capsules USP 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg, the Company's generic equivalent of Symbyax®.

Symbyax® is marketed by Lilly USA and approved for the acute treatment of treatment-resistant depression and bipolar I depression in adults. The brand product had annual sales of approximately $82 million in the United States, based on IMS sales data.

Source: Teva Pharmaceutical Industries Ltd.

Posted in: Medical Condition News | Pharmaceutical News

Tags: Biotechnology, Depression, Generic Drug, Medicaid, Medicare, Mental Health, Olanzapine, Oncology, Pain, Pharmaceuticals, Protonix, Respiratory

Comments (0)

Download PDF Copy

Suggested Reading

Persistent and increasing depression linked to higher mortality risk in Chinese adults

Persistent and increasing depression linked to higher mortality risk in Chinese adults

Research highlights depression trends in community-dwelling older adults

Research highlights depression trends in community-dwelling older adults

AI model combines speech and brain activity to diagnose depression

AI model combines speech and brain activity to diagnose depression

Depression increases chances of experiencing menstrual pain

Depression increases chances of experiencing menstrual pain

Study suggests beta-blockers may elevate depression symptoms in post-MI patients

Study suggests beta-blockers may elevate depression symptoms in post-MI patients

Unraveling the psychological impact of COVID-19 on young minds

Unraveling the psychological impact of COVID-19 on young minds

Study: Nearly 75% of Australian adolescents experience depression or anxiety

Study: Nearly 75% of Australian adolescents experience depression or anxiety

Exercise reduces severity of postpartum depression and anxiety

Exercise reduces severity of postpartum depression and anxiety

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Research highlights immune system's role in depression